结直肠癌中PD-L2表达的临床病理分析
Clinicopathological analysis of PD-L2 expression in colorectal cancer.
作者信息
Guo Peng-Da, Sun Zhong-Wen, Lai Hui-Jun, Yang Jie, Wu Ping-Ping, Guo Yun-Di, Sun Jing
机构信息
Institute of Medical Technology, Suzhou Vocational Health College, Suzhou, Jiangsu 215009, China,
Department of Ultrasound, Suzhou Traditional Chinese Medicine, Suzhou, Jiangsu 215007, China.
出版信息
Onco Targets Ther. 2018 Nov 1;11:7635-7642. doi: 10.2147/OTT.S177329. eCollection 2018.
BACKGROUND
(PD-L2), a ligand of programmed cell death protein 1 (PD-1), is an inhibitory receptor of T cells and activated B cells. Many studies have focused on PD-L1, another ligand of PD-1, and the prognostic significance of PD-L1 has been reported in many tumors. However, the expression of PD-L2 in relation to clinical outcomes has not been fully investigated in cancer patients.
PATIENTS AND METHODS
In this study, we investigated the expression of PD-L2 via immunohistochemistry (IHC) in the pathological specimens of 348 patients treated for colorectal cancer (CRC).
RESULTS
Strong PD-L2 expression was found in the cancer tissues from 41% of the CRC patients who also had a high TNM stage and carcinoembryonic antigen (CEA) concentration. We also carried out functional studies in vitro, which showed that PD-L2 did not influence the growth of the CRC cell line HCT116, but increased cell invasion.
CONCLUSION
Collectively, these findings suggest that PD-L2 may be a potential therapeutic target for CRC.
背景
程序性死亡蛋白1（PD-1）的配体之一程序性死亡配体2（PD-L2）是T细胞和活化B细胞的抑制性受体。许多研究聚焦于PD-1的另一种配体程序性死亡配体1（PD-L1），且在许多肿瘤中已报道了PD-L1的预后意义。然而，癌症患者中PD-L2表达与临床结局的关系尚未得到充分研究。
患者与方法
在本研究中，我们通过免疫组织化学（IHC）检测了348例接受结直肠癌（CRC）治疗患者的病理标本中PD-L2的表达。
结果
在41%的CRC患者的癌组织中发现了强PD-L2表达，这些患者还具有高TNM分期和癌胚抗原（CEA）浓度。我们还进行了体外功能研究，结果表明PD-L2不影响CRC细胞系HCT116的生长，但增加细胞侵袭。
结论
总体而言，这些发现提示PD-L2可能是CRC的一个潜在治疗靶点。
Zotero 插件